February 2, 2021

Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021)

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): antibodies, public health policy, treatment

Around 75% of the 641,000 COVID-19 monoclonal antibody (mAb) therapies allocated by the Department of Health and Human Services to states and local territories were not administered in the period before January 6, 2021. As a response, a rapid consultation by the National Academies of Sciences, Engineering, and Medicine identified potential barriers, including the limited evidence on the clinical benefits, the time-sensitive requirements of mAb delivery, cost, and the lack of transfusion infrastructure to administer the mAb therapies. The consultation describes allocation models that address barriers to access and equitable distribution, and offers examples currently practiced in health systems in Pennsylvania and Massachusetts.

Fineberg et al. (Jan 29, 2021). Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021). National Academies of Sciences, Engineering, and Medicine. https://doi.org/10.17226/26063